Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.75 +7.4%	$2.46	$0.55 ▼ $6.19	$137.15M	3	367,605 shs	281,705 shs
FATE Fate Therapeutics	$1.15 +3.6%	$1.13	$0.66 ▼ $4.20	$132.63M	2.24	1.52 million shs	1.84 million shs
HURA TuHURA Biosciences	$3.25 +11.7%	$2.62	$1.80 ▼ $8.40	$162.65M	0.04	790,028 shs	612,913 shs
IGC IGC Pharma	$0.36 +11.0%	$0.34	$0.25 ▼ $0.48	$33.15M	1.48	913,992 shs	214,616 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	0.00%	+3.55%	-10.26%	+92.31%	-9.33%
FATE Fate Therapeutics	0.00%	+5.50%	-8.00%	-0.86%	-70.59%
HURA TuHURA Biosciences	0.00%	+6.21%	+14.44%	+14.84%	+324,999,900.00%
IGC IGC Pharma	0.00%	-1.63%	-3.72%	+7.74%	-8.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.3509 of 5 stars	3.0	0.0	0.0	1.8	1.7	0.0
FATE Fate Therapeutics	4.0155 of 5 stars	3.1	2.0	4.7	2.0	2.5	0.6
HURA TuHURA Biosciences	1.4779 of 5 stars	3.7	0.0	0.0	1.9	0.0	0.0
IGC IGC Pharma	1.7564 of 5 stars	3.5	0.0	0.0	1.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	71.43% Upside
FATE Fate Therapeutics	2.14	Hold	$3.30	186.96% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	289.74% Upside
IGC IGC Pharma	3.00	Buy	$3.88	970.44% Upside

Current Analyst Ratings Breakdown

Latest IGC, CTOR, FATE, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
FATE Fate Therapeutics	$13.63M	9.73	N/A	N/A	$2.80 per share	0.41
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
IGC IGC Pharma	$1.33M	24.77	N/A	N/A	$0.08 per share	4.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	11/11/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
IGC IGC Pharma	-$13M	-$0.07	N/A	N/A	N/A	-714.16%	-122.44%	-88.40%	N/A

Latest IGC, CTOR, FATE, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IGC IGC Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.12	0.35	0.02
FATE Fate Therapeutics	N/A	8.04	8.04
HURA TuHURA Biosciences	N/A	0.83	0.83
IGC IGC Pharma	0.02	1.15	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
FATE Fate Therapeutics	97.54%
HURA TuHURA Biosciences	0.62%
IGC IGC Pharma	3.87%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
FATE Fate Therapeutics	5.51%
HURA TuHURA Biosciences	0.20%
IGC IGC Pharma	31.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	49.95 million	N/A
IGC IGC Pharma	61	90.81 million	54.60 million	N/A

IGC, CTOR, FATE, and HURA Headlines

Recent News About These Companies

IGC Pharma, Inc.: IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

August 19, 2025 | finanznachrichten.de

IGC Pharma reports Q1 EPS (2c) vs. (3c) last year

August 19, 2025 | msn.com

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

August 19, 2025 | accessnewswire.comA

IGC Pharma (NYSEMKT:IGC) Shares Up 16.8% - Time to Buy?

August 19, 2025 | americanbankingnews.com

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

August 14, 2025 | zacks.com

IGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

August 13, 2025 | finanznachrichten.de

IGC Pharma highlights preclinical data on IGC-M3

August 12, 2025 | msn.com

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

August 12, 2025 | accessnewswire.comA

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

August 5, 2025 | accessnewswire.comA

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

July 23, 2025 | accessnewswire.comA

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

July 21, 2025 | accessnewswire.comA

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...

July 12, 2025 | morningstar.comM

IGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

July 11, 2025 | finanznachrichten.de

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

July 10, 2025 | accessnewswire.comA

Earnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com

July 2, 2025 | investing.com

IGC Pharma earnings matched, revenue fell short of estimates

July 2, 2025 | investing.com

Earnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com UK

July 2, 2025 | uk.investing.com

IGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

June 30, 2025 | finanznachrichten.de

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

June 30, 2025 | accessnewswire.comA

IGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - FinanzNachrichten.de

June 28, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IGC, CTOR, FATE, and HURA Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.75 +0.12 (+7.36%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.72 -0.03 (-2.00%)

As of 08/22/2025 07:54 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Fate Therapeutics NASDAQ:FATE

$1.15 +0.04 (+3.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.87%)

As of 08/22/2025 06:56 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

TuHURA Biosciences NASDAQ:HURA

$3.25 +0.34 (+11.68%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.22 -0.03 (-0.89%)

As of 08/22/2025 07:56 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

IGC Pharma NYSEMKT:IGC

$0.36 +0.04 (+11.01%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.36 0.00 (-0.83%)

As of 08/22/2025 07:48 PM Eastern

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time